TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05215015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD33/CLL1 CAR-NK Cells
Description: The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
Study: NCT03777917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance®
Description: Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
Study: NCT02585648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo Gel and Thealoz Duo eye drops
Description: Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo Gel and Thealoz Duo eye drops
Description: Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo eye drops
Description: Thealoz Duo eye drops during the day (4 to 6 drops per day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo eye drops
Description: Thealoz Duo eye drops during the day (4 to 6 drops per day)
Study: NCT02087813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-antitrypsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
Study: NCT02211196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Receive evidence-based tobacco cessation strategies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study: NCT02242175

Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose breath test (hydrogen breath test)
Description: Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.

Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose breath test (hydrogen breath test)
Description: Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
Study: NCT01287221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 300 mg, 2 times daily
Study: NCT01955499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT01138384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Daily oral dosing at assigned dose beginning day 3 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Daily oral dosing at assigned dose beginning day 1 cycle 1.
Study: NCT00000170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: Patching
Study: NCT02611869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Description: Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF ablation
Description: Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
Study: NCT04486703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with music
Description: physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with music
Description: physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
Study: NCT03108027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Study: NCT00911638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Description: Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only
Study: NCT03942094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily
Study: NCT04012970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual spinal mobilisations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual spinal mobilisations
Study: NCT01960738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A pre-dive checklist
Description: The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
Study: NCT01287221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03340415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabilitation plan
Description: early weight bearing after surgery
Study: NCT03615833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
Study: NCT00110669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding.
Study: NCT04872296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ankle Motion (CAM) boot
Description: A CAM boot will be worn on the affected ankle to allow weight bearing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ankle Motion (CAM) boot
Description: A CAM boot will be worn on the affected ankle to allow weight bearing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard physical therapy protocol will be started at 6 weeks after surgery
Study: NCT02489656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Loop Ureteral stent endoscopic placement.
Description: A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Loop Ureteral stent endoscopic placement.
Description: A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
Study: NCT03737344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-1Ra Kineret®
Description: Kineret® 100 mg in 0.67 ml Prefilled Syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IL-1Ra Placebo
Description: Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
Study: NCT02324049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBC-103
Study: NCT02618512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBC-103
Description: SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
Study: NCT04698954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Improving self-Management Strategy
Description: The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
Study: NCT03170765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
Study: NCT02625363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Ref - Std
Description: First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Ref and 450 ml water
Description: First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread with 250 ml water
Description: First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread and 700 ml water
Description: Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study: NCT04952038

Intervention type: BEHAVIORAL
Intervention: sleep disorder
Description: ALS patients with or without sleep disorder
Study: NCT01485380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
Study: NCT01945775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: Until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's-Choice
Description: Capecitabine, Eribulin, Gemcitabine or Vinorelbine
Study: NCT05315375

Intervention type: DEVICE
Intervention: corpectomy
Description: vertebral corpectomy using expandable cage
Study: NCT02649192

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza virus vaccine
Description: Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus vaccine
Description: Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins A and D
Description: The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
Study: NCT03164083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients with knee joint osteoarthritis who underwent intra articular placebo injection
Study: NCT01281098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)
Description: Panretinal Photocoagulation (PRP)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)
Description: Panretinal Photocoagulation (PRP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of pegaptanib
Description: Intravitreous injection of pegaptanib
Study: NCT00892606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Patients will receive 0.2 mg/kg of methadone IV immediately after intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
Study: NCT02322294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucodia™

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01787318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
Study: NCT03833570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapid Release Capsules Melatonin, 10 mg
Description: Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconaz oral gel
Description: Antifungal agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconaz oral gel
Description: Antifungal agent
Study: NCT02211196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01455298

Intervention type: OTHER
Group type: OTHER
Intervention: Transient Elastography and fibrotest
Description: a Transient Elastography and an ultrasound are performed.
Study: NCT01782430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: - standard oxygenation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: - standard oxygenation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: - standard oxygenation
Study: NCT05056662

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR
Description: Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR
Description: Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR
Description: Enrolled patients will undergo invasive functional evaluation of coronary stenosis followed by percutaneous revascularization if appropriate. Patients in Group 3 will have target lesion re-assessed using either PdPa, FFR, iFR or contrast FFR.
Study: NCT04716868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Fructans 5 g
Description: Agave tequilana Weber blue variety 5 g once a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Fructans 10 g
Description: Agave tequilana Weber blue variety 10 g once a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Fructans 5 g + Maltodextrin 10 g
Description: Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium plantago
Description: Psyllium plantago 15 g once a day for 8 weeks
Study: NCT03020589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: See description in arm/group sections
Study: NCT04226950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Interferon Alpha
Description: Recombinant Interferon Alpha, with an initial dose of 300 wu twice a week. Other interferons that have been listed can be used if Recombinant Interferon Alpha (300 wu) is not available, and the specific dose will be determined by the researchers;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: Pegylated Interferon Alfa-2b, with an initial dose of 135 ug once a week (body surface area \< 1.73 m2) or 180 ug once a week ( body surface area≥1.73 m2).
Study: NCT03833570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBC oral spray
Description: Topical anesthetics and anti-inflammatory agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oracure gel
Description: Topical analgesic gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracure gel
Description: Topical analgesic gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkamisr sachets
Description: Sodium bicarbonate mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkamisr sachets
Description: Sodium bicarbonate mouthwash
Study: NCT02960646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo CD45RA depleted peripheral blood stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI